Industry Predictions for 2020
January 9, 2020

Medlior is looking forward to another year of innovation in health outcomes research

2019 has been one of Medlior’s most successful years to date and we can’t wait to see what is in store for us in 2020!

With our core purpose of positively impacting global health through rigorous research, we head into 2020 with a unique perspective on upcoming initiatives and trends within the industry.

Here are six predictions we think you’ll see in the coming year.

  1. Increase use of AI and machine learning for big data projects
    AI has the ability to change the world and the health industry is no different. When it comes to big data projects, AI and machine learning increase the speed, accuracy and insights of big data analyses.
  2. Increase in utilization of Real World Evidence 
    Real World Evidence continues to inform decision-making across the health system to improve patient outcomes and inform health care spending, we believe this will only continue to grow in 2020 with novel data sources and collaborations across industry sectors.
  3. Quality standards for Real World Evidence 
    Increasing use of Real World Evidence for reimbursement decisions has led to a call for quality standards for how these studies should be conducted to meet the needs of HTA bodies, where it is often unclear how Real World Evidence is evaluated to inform reimbursement decisions.
  4. Increase in market access for gene therapies
    Novel therapies are coming to market with curative outcomes but they are also creating uncertainty with regards to pricing and lack of mature data. The opportunity to utilize Real World Evidence for conditional reimbursement and long-term follow-up may facilitate access to these ground-breaking therapies.
  5. Expanding indications for diverse populations not included in clinical trials 
    Children, pregnant women, elderly or those with severe or comorbid diseases are typically not included in clinical trials. Real World Evidence presents a tremendous opportunity to increase our understanding of the burden of disease and effective therapies, which will improve treatment options and patient outcomes for all populations.
  6. Increase in Patient Support Programs for patient-centric outcomes
    The majority of Real World Evidence that is discussed today is coming from administrative health system data sources which are not collected for research purposes and therefore many key clinical outcomes (disease severity, disease progression or patient-reported outcomes) are missing. Although data sources such as patient registries are an excellent source of Real World Evidence, they sometimes can lack research quality data or governance structures to share their data. On the other hand, Patient Support Programs are another avenue for collecting patient-centric data for research purposes and will allow industry an opportunity to demonstrate the value of their therapies through patient outcomes not captured in administrative sources.

Medlior’s multidisciplinary team is looking forward to offering valuable insights to a myriad of projects in 2020. With our expertise stemming from roles in health systems, academia and industry, we can bring value through our robust research methodology to any project. Contact us today to see how we can help you!